ArticlePharmacoEconomics - open2025

Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in High-Risk Older Adults in Japan.

Hardik Goswami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.